Patent Pooling and the Experience of the MPP – A model for sharing the value of innovation to ensure access
MPP's ED Greg Perry's presentation at IFPMA event on January 29, 2014.
Market Approaches for Innovation and AccessUNITAID
The Gilead Sciences Presentation during the session "Market Interventions for Innovation and Access", UN High Level Meeting on HIV/AIDS
New York, 9 June 2011
“Challenges of biosimilar product development and experience gained”
Shows the development process for biosimilars, focusing specifically on the company’s experience
The GSMA represents the interests of nearly 800 mobile operators and 200 companies in the mobile ecosystem worldwide. The GSMA mHealth Programme aims to support more affordable and accessible healthcare through mobile technologies by running trials, fostering relationships between healthcare and mobile industries, promoting interoperability and growth, and showcasing solutions through events. Interoperability is fundamental to the success of mHealth by allowing connectivity between back-end systems, devices, providers and industries through mature standards.
At least 400 million people worldwide lack access to essential health services and 2 billion cannot afford the medicines they need. Meanwhile, the global cost of healthcare has jumped to 6.5 trillion US dollars. Access is a huge and complex issue, which affects both developing and developed countries.
Today Carol Lynch, our Global Head of Biopharmaceuticals, gave a keynote address to the European Biosimilars Group highlighting how biosimilars can help transform patient outcomes and calling for all stakeholders to work together to build trust and confidence. You can read the presentation here
Overcoming Unmet Needs in Infectious DiseaseCovance
Overcoming Unmet Needs In Infectious Disease Optimize your antibiotic trials with an experienced and trusted partner Each year approximately two million people in the U.S. alone become infected with multi-drug-resistant bacteria and at least 23,000 of these die as a direct result of these infections. There is an urgent need to bring new antibiotics to the market, yet the pipeline for new antibiotics has dwindled.
The document discusses the implications of drug development and access including increased expectations which can place pressures on physicians and the healthcare system. It also notes the need to develop knowledge and apply it faster and cheaper while ensuring certain groups are not left out. Finally, the document calls for dialogue to better understand the Canadian marketplace from the perspective of patients, products, policy, restraints, and opportunities.
Market Approaches for Innovation and AccessUNITAID
The Gilead Sciences Presentation during the session "Market Interventions for Innovation and Access", UN High Level Meeting on HIV/AIDS
New York, 9 June 2011
“Challenges of biosimilar product development and experience gained”
Shows the development process for biosimilars, focusing specifically on the company’s experience
The GSMA represents the interests of nearly 800 mobile operators and 200 companies in the mobile ecosystem worldwide. The GSMA mHealth Programme aims to support more affordable and accessible healthcare through mobile technologies by running trials, fostering relationships between healthcare and mobile industries, promoting interoperability and growth, and showcasing solutions through events. Interoperability is fundamental to the success of mHealth by allowing connectivity between back-end systems, devices, providers and industries through mature standards.
At least 400 million people worldwide lack access to essential health services and 2 billion cannot afford the medicines they need. Meanwhile, the global cost of healthcare has jumped to 6.5 trillion US dollars. Access is a huge and complex issue, which affects both developing and developed countries.
Today Carol Lynch, our Global Head of Biopharmaceuticals, gave a keynote address to the European Biosimilars Group highlighting how biosimilars can help transform patient outcomes and calling for all stakeholders to work together to build trust and confidence. You can read the presentation here
Overcoming Unmet Needs in Infectious DiseaseCovance
Overcoming Unmet Needs In Infectious Disease Optimize your antibiotic trials with an experienced and trusted partner Each year approximately two million people in the U.S. alone become infected with multi-drug-resistant bacteria and at least 23,000 of these die as a direct result of these infections. There is an urgent need to bring new antibiotics to the market, yet the pipeline for new antibiotics has dwindled.
The document discusses the implications of drug development and access including increased expectations which can place pressures on physicians and the healthcare system. It also notes the need to develop knowledge and apply it faster and cheaper while ensuring certain groups are not left out. Finally, the document calls for dialogue to better understand the Canadian marketplace from the perspective of patients, products, policy, restraints, and opportunities.
Sandoz reached 520 million patients worldwide in 2015 and aims to reach one billion patients by expanding access to medicine. The presentation discusses the global challenge of access to healthcare, with over 2 billion people unable to access needed medicines. Sandoz is uniquely positioned within Novartis to help solve the access challenge through its broad portfolio, focus on priority markets, and leadership in generics, biosimilars, and anti-infectives.
The Impact of High Cost Oncology DrugsJoshua Jacob
Oncology drugs are extremely expensive, with some costing over $100,000 per treatment course. This high cost is due to drug development costs, market exclusivity from patents, and companies prioritizing profits. However, these drug prices strain healthcare budgets and reduce access. To address this, governments are implementing value-based drug pricing and health technology assessments. In the future, personalized treatments and collaborations may help control costs while continuing to advance cancer care.
The document outlines several past and proposed models for a national pharmacare program in Canada, including:
1. The 2003 First Ministers Health Accord and National Pharmaceuticals Strategy proposed universal coverage with two options for income-based cost sharing thresholds but negotiations failed.
2. The 2002 Kirby and Romanow reports recommended a $1500 annual catastrophic drug coverage threshold but their recommendations did not move forward.
3. The 2009 Canadian Treatment Action Council model proposed a universal catastrophic drug plan with income-based cost sharing, centralized management, and funding from governments, employers, and manufacturers.
The role of Sustainable Procurement in the Health Sector in global health ini...UN SPHS
Presentation given by Mirjana Milic (Associate Coordinator,
Secretariat of the UN informal Interagency Task Team on Sustainable Procurement in the Health Sector - SPHS) at the 75th FIP World Congress of Pharmacy and Pharmaceutical Sciences, about the role of Sustainable Procurement in the Health Sector in global health initiatives - SPHS
Gilead has signed agreements with 11 Indian generic drug companies to produce generic versions of Gilead's hepatitis C drugs for 101 developing countries. The agreements allow the generic companies to set their own prices and provide a full technology transfer to quickly scale up production. Royalties from the generic companies will support developing world access programs. Gilead is also working directly with local manufacturers in Egypt and Pakistan and offers reduced prices for branded drugs in these countries to help expand access to hepatitis C treatment.
African Food Safety Index: Evaluation and validationILRI
Presentation by Silvia Alonso, Winta Sintayehu, Abraham Getachew, Wezi Chunga, Florence Mutua, Kebede Amenu, Filipe De Souza, Peace Mutuwa, Ibrahim Gariba, Yohannes Zelalem, Ian Dohoo, Delia Grace and Amare Ayalew at the virtual 2020 Agriculture, Nutrition and Health (ANH) Academy Week research conference, 30 June–2 July 2020.
The Reproductive Health Supplies Coalition (RHSC) and its Maternal Health Supplies Caucus work to ensure global access to affordable, high-quality reproductive and maternal health supplies. The RHSC has 328 members from various sectors and its vision is that all people can access contraceptive supplies for better health. The Maternal Health Supplies Caucus was formed in 2012 to address bottlenecks undermining access to essential medicines for maternal health. The Caucus has published briefs on key maternal medicines and business cases to increase investment in their production. Persistent challenges to access include issues with policy harmonization, forecasting, quality assurance, financing, and specific product presentations or storage concerns. Next steps involve market shaping strategies and field testing
This document discusses regional plans for biofortification in Africa. It outlines the Framework for African Food Security which aims to increase resilience through decreasing food insecurity and linking vulnerable people to agricultural opportunities. The plans focus on improved risk management, increased and more affordable food production, economic opportunities, and diversified, more nutritious diets. Regional coordination is seen as key through high-level political support, shared priorities and accountability, and incentives for private sector investment in nutrition-sensitive value chains. Information sharing and advocacy are also emphasized to address preferences and overcome constraints such as facilitating trade of biofortified crops. Partnerships between organizations are proposed to advocate for and analyze impacts of biofortification at regional and national levels.
The document discusses spreading innovation in health care through partnerships with various local organizations to improve health and generate economic growth. It lists the local partners that guide their innovation work, including provider trusts, commissioners, strategic clinical networks, universities, and others. It also discusses efforts to engage patients and the public, including recruiting patients to trial mobile health apps, launching ambassadors for atrial fibrillation, and forming patient representative groups.
Paper presented by GSK's Developing Countries Operating UnitPharmaAfrica
Presentation by GSK's Developing Countries Operating Unit made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Scaling-up the impact of aflatoxin research in Africa. The role of social sci...Francois Stepman
24 - 27 June 2018. Mombasa (Kenya). The 2nd African Symposium on Mycotoxicology entitled “Mitigating mycotoxin contamination in the African food and feed chain”
This document outlines an IWMI Africa Uptake Strategy. It defines research uptake as the effective utilization of research-based evidence by decision makers. The strategy aims to have a clear impact, demonstrate the value of IWMI's research, and achieve greater success. Key elements include engaging target audiences like policymakers, packaging outputs, and monitoring outcomes. Implementation occurs at the project level and by developing knowledge products and engaging with groups like NEPAD, FARA, and national governments to influence policy and irrigation practices. The strategy recognizes limitations like directly impacting end users.
Addressing Anemia Full Spectrum_Koporc_5.11.11CORE Group
The document summarizes the results of the first global NGO deworming inventory. It found that NGOs donated 127.9 million deworming treatments in 2009 but only reported 20.8 million unique treatments to the inventory. A WHO working group concluded the inventory was useful for identifying the scale of NGO deworming activities. It recommended continuing the inventory and encouraging more NGO participation to help coordinate deworming efforts and assess unmet needs.
BPEX Health initiatives - benefits for breedersSam Hoste
Regional pig health schemes have been established in several areas of England since 2009 with the goals of improving pig health and collaboration across the industry. The schemes are producer-driven and aim to improve biosecurity, disease monitoring and information sharing. Central elements for their success include high producer engagement, motivated farmers, collaboration between neighbors, and involvement of local veterinarians. The schemes establish regional steering committees and organize smaller cluster groups of nearby producers to jointly address health priorities and apply for funding. While challenges include maintaining funding and overcoming apprehensive producers, the programs benefit the industry by expanding disease-free areas and improving whole chain communication.
Food safety research for development in sub-Saharan Africa: Tapping the exper...ILRI
Poster by Kristina Roesel, Kohei Makita and Delia Grace presented at the international symposium of the German Federal Institute of Risk Assessment (BfR), Berlin, Germany, 30 November 2017.
Sets out the five core principles which guide the operation of the Medicines Transparency Alliance (MeTA) in efforts to increase transparency, accountability and governance around the supply of essential medicines.
Forwarding Wisconsin's Fuel Choice is a $520,000 two-year program designed to implement policy, barrier reduction, training, and educational initiatives to significantly expand the alternative fuels market in Wisconsin. The program is a partnership between the Wisconsin State Energy Office, Wisconsin Clean Cities, and the Wisconsin State Technical College System.
Sandoz is a global leader in generic pharmaceuticals and is part of the Novartis Group. In 2011, Sandoz had sales of $9.5 billion and reached over 400 million patients worldwide. Sandoz operates in 140 countries with around 25,000 employees and has a portfolio of over 1,100 compounds and 23,500 stock-keeping units. The document discusses Sandoz's leadership in various therapeutic areas and technologies. It also highlights Sandoz's commitment to growth in Africa through partnerships and projects aimed at improving patient care.
A project to increase access to HIV treatment in middle income countries. The project funded by UNITAID is led by International Treatment Preparedness Coaliton (ITPC). The presentation is prepared by Solange Baptiste from ITPC.
The presentation explains why the project focuses on middle-income countries, explains the intervention, describing objectives and outcomes.
Licensing for Access: Compulsory and
Humanitarian Licenses
Cristina de A. Possas
Conference FDUSP UAEM
The Right to Health: the Role of Universities
in the access to medicines
São Paulo, August 17, 2010
Sandoz reached 520 million patients worldwide in 2015 and aims to reach one billion patients by expanding access to medicine. The presentation discusses the global challenge of access to healthcare, with over 2 billion people unable to access needed medicines. Sandoz is uniquely positioned within Novartis to help solve the access challenge through its broad portfolio, focus on priority markets, and leadership in generics, biosimilars, and anti-infectives.
The Impact of High Cost Oncology DrugsJoshua Jacob
Oncology drugs are extremely expensive, with some costing over $100,000 per treatment course. This high cost is due to drug development costs, market exclusivity from patents, and companies prioritizing profits. However, these drug prices strain healthcare budgets and reduce access. To address this, governments are implementing value-based drug pricing and health technology assessments. In the future, personalized treatments and collaborations may help control costs while continuing to advance cancer care.
The document outlines several past and proposed models for a national pharmacare program in Canada, including:
1. The 2003 First Ministers Health Accord and National Pharmaceuticals Strategy proposed universal coverage with two options for income-based cost sharing thresholds but negotiations failed.
2. The 2002 Kirby and Romanow reports recommended a $1500 annual catastrophic drug coverage threshold but their recommendations did not move forward.
3. The 2009 Canadian Treatment Action Council model proposed a universal catastrophic drug plan with income-based cost sharing, centralized management, and funding from governments, employers, and manufacturers.
The role of Sustainable Procurement in the Health Sector in global health ini...UN SPHS
Presentation given by Mirjana Milic (Associate Coordinator,
Secretariat of the UN informal Interagency Task Team on Sustainable Procurement in the Health Sector - SPHS) at the 75th FIP World Congress of Pharmacy and Pharmaceutical Sciences, about the role of Sustainable Procurement in the Health Sector in global health initiatives - SPHS
Gilead has signed agreements with 11 Indian generic drug companies to produce generic versions of Gilead's hepatitis C drugs for 101 developing countries. The agreements allow the generic companies to set their own prices and provide a full technology transfer to quickly scale up production. Royalties from the generic companies will support developing world access programs. Gilead is also working directly with local manufacturers in Egypt and Pakistan and offers reduced prices for branded drugs in these countries to help expand access to hepatitis C treatment.
African Food Safety Index: Evaluation and validationILRI
Presentation by Silvia Alonso, Winta Sintayehu, Abraham Getachew, Wezi Chunga, Florence Mutua, Kebede Amenu, Filipe De Souza, Peace Mutuwa, Ibrahim Gariba, Yohannes Zelalem, Ian Dohoo, Delia Grace and Amare Ayalew at the virtual 2020 Agriculture, Nutrition and Health (ANH) Academy Week research conference, 30 June–2 July 2020.
The Reproductive Health Supplies Coalition (RHSC) and its Maternal Health Supplies Caucus work to ensure global access to affordable, high-quality reproductive and maternal health supplies. The RHSC has 328 members from various sectors and its vision is that all people can access contraceptive supplies for better health. The Maternal Health Supplies Caucus was formed in 2012 to address bottlenecks undermining access to essential medicines for maternal health. The Caucus has published briefs on key maternal medicines and business cases to increase investment in their production. Persistent challenges to access include issues with policy harmonization, forecasting, quality assurance, financing, and specific product presentations or storage concerns. Next steps involve market shaping strategies and field testing
This document discusses regional plans for biofortification in Africa. It outlines the Framework for African Food Security which aims to increase resilience through decreasing food insecurity and linking vulnerable people to agricultural opportunities. The plans focus on improved risk management, increased and more affordable food production, economic opportunities, and diversified, more nutritious diets. Regional coordination is seen as key through high-level political support, shared priorities and accountability, and incentives for private sector investment in nutrition-sensitive value chains. Information sharing and advocacy are also emphasized to address preferences and overcome constraints such as facilitating trade of biofortified crops. Partnerships between organizations are proposed to advocate for and analyze impacts of biofortification at regional and national levels.
The document discusses spreading innovation in health care through partnerships with various local organizations to improve health and generate economic growth. It lists the local partners that guide their innovation work, including provider trusts, commissioners, strategic clinical networks, universities, and others. It also discusses efforts to engage patients and the public, including recruiting patients to trial mobile health apps, launching ambassadors for atrial fibrillation, and forming patient representative groups.
Paper presented by GSK's Developing Countries Operating UnitPharmaAfrica
Presentation by GSK's Developing Countries Operating Unit made at the Euro-Africa Health Investment Conference, March 26 - 27, 2013, London, United Kingdom.
Scaling-up the impact of aflatoxin research in Africa. The role of social sci...Francois Stepman
24 - 27 June 2018. Mombasa (Kenya). The 2nd African Symposium on Mycotoxicology entitled “Mitigating mycotoxin contamination in the African food and feed chain”
This document outlines an IWMI Africa Uptake Strategy. It defines research uptake as the effective utilization of research-based evidence by decision makers. The strategy aims to have a clear impact, demonstrate the value of IWMI's research, and achieve greater success. Key elements include engaging target audiences like policymakers, packaging outputs, and monitoring outcomes. Implementation occurs at the project level and by developing knowledge products and engaging with groups like NEPAD, FARA, and national governments to influence policy and irrigation practices. The strategy recognizes limitations like directly impacting end users.
Addressing Anemia Full Spectrum_Koporc_5.11.11CORE Group
The document summarizes the results of the first global NGO deworming inventory. It found that NGOs donated 127.9 million deworming treatments in 2009 but only reported 20.8 million unique treatments to the inventory. A WHO working group concluded the inventory was useful for identifying the scale of NGO deworming activities. It recommended continuing the inventory and encouraging more NGO participation to help coordinate deworming efforts and assess unmet needs.
BPEX Health initiatives - benefits for breedersSam Hoste
Regional pig health schemes have been established in several areas of England since 2009 with the goals of improving pig health and collaboration across the industry. The schemes are producer-driven and aim to improve biosecurity, disease monitoring and information sharing. Central elements for their success include high producer engagement, motivated farmers, collaboration between neighbors, and involvement of local veterinarians. The schemes establish regional steering committees and organize smaller cluster groups of nearby producers to jointly address health priorities and apply for funding. While challenges include maintaining funding and overcoming apprehensive producers, the programs benefit the industry by expanding disease-free areas and improving whole chain communication.
Food safety research for development in sub-Saharan Africa: Tapping the exper...ILRI
Poster by Kristina Roesel, Kohei Makita and Delia Grace presented at the international symposium of the German Federal Institute of Risk Assessment (BfR), Berlin, Germany, 30 November 2017.
Sets out the five core principles which guide the operation of the Medicines Transparency Alliance (MeTA) in efforts to increase transparency, accountability and governance around the supply of essential medicines.
Forwarding Wisconsin's Fuel Choice is a $520,000 two-year program designed to implement policy, barrier reduction, training, and educational initiatives to significantly expand the alternative fuels market in Wisconsin. The program is a partnership between the Wisconsin State Energy Office, Wisconsin Clean Cities, and the Wisconsin State Technical College System.
Sandoz is a global leader in generic pharmaceuticals and is part of the Novartis Group. In 2011, Sandoz had sales of $9.5 billion and reached over 400 million patients worldwide. Sandoz operates in 140 countries with around 25,000 employees and has a portfolio of over 1,100 compounds and 23,500 stock-keeping units. The document discusses Sandoz's leadership in various therapeutic areas and technologies. It also highlights Sandoz's commitment to growth in Africa through partnerships and projects aimed at improving patient care.
A project to increase access to HIV treatment in middle income countries. The project funded by UNITAID is led by International Treatment Preparedness Coaliton (ITPC). The presentation is prepared by Solange Baptiste from ITPC.
The presentation explains why the project focuses on middle-income countries, explains the intervention, describing objectives and outcomes.
Licensing for Access: Compulsory and
Humanitarian Licenses
Cristina de A. Possas
Conference FDUSP UAEM
The Right to Health: the Role of Universities
in the access to medicines
São Paulo, August 17, 2010
The document summarizes a presentation on licensing for access to medicines and compulsory/humanitarian licenses. It discusses the global HIV/AIDS scenario, challenges in access to antiretroviral (ARV) treatment, and Brazil's success in universal access through price reductions from compulsory licenses. However, sustainability issues remain as expenditures on patented third-line ARVs are increasing exponentially. Alternative incentives to innovation and more flexible intellectual property regimes are needed to promote access to medicines globally.
A Rare International Dialogue (Saturday May 11, 2019)
Drivers of Drug Development – Regulatory Collaboration
European regulatory approaches to drugs for rare diseases - Daniel O’Connor, European Medicines Agency/Medicines and Healthcare products Regulatory Agency, UK
Geneva Pharma Forum on Pharmacovigilance: Partnering for
Patient Safety (Geneva, 20 November 2012), Jeremiah Mwangi, Director, Policy and External Affairs, IAPO
The document discusses WHO guidelines on rational medicine use and types of irrational medicine use. It notes that more than half of global medicine use is irrational, costing money and reducing treatment effectiveness. Irrational use includes polypharmacy, inappropriate antibiotic use, overuse of injections, and self-medication without prescriptions. The document lists several causes of irrational use, such as the natural history of illnesses, pseudo-logic, advertising influence on prescribers, and the perception that injections are always better than oral medications. Addressing irrational medicine use is important for improving health outcomes and efficient use of resources.
Access to Medicines: A Role for Our Universities
MedicinesAugust 17, 2010Universities Allied for Essential MedicinesPresentation for Universidade de SÃO PAULO -USP
This document discusses access to medicines and the role that universities can play in improving access. It notes that over 2 billion people lack access to life-saving drugs and that high medicine prices are a major barrier. While medical research has improved health in developed countries, people in developing countries have not benefited as much. The implementation of TRIPS requiring intellectual property protections globally has reduced access to affordable generic medicines. The document argues that as public universities contribute significantly to medical research and drug development, they are well positioned to promote access by adopting patent and licensing policies that facilitate generic competition and ensure people in developing countries can afford essential medicines.
Presentation on Concept and structure of MeTA by Wilbert Bannenberg, MeTA Technical Director during the MeTA Country Sharing Meeting, London, 8 December 2009.
Civil society organizations play an important role in expanding access to drugs through patent oppositions. The document discusses how civil society pressure led India to include public health safeguards in its 2005 patent system. It then describes how civil society actors filed successful patent challenges in India from 2006-2017 for key HIV drugs, enabling generic production and resulting in price reductions of 51-89% for those drugs. These challenges generated cost savings of $500 million for lower-income countries, enough money to treat over 1 million people. The document concludes by noting civil society now leads patent opposition work in nearly 50 countries, but also outlines some limitations of the patent opposition process.
Increasing access to medicines, presentation by Edith Andrews Annan of World Health Organization (WHO) during the MeTA Ghana, CSO & media orientation workshop, 16 April 2009.
Global pharmaceutical companies are modeled with a supply chain, which ensures that the right drug reaches the right people at the right time and in the right condition. The supply chain also ensures 100% product availability at optimum cost by carrying huge inventory, which maintains 100% fill rate. Manufacturers are trying to cut down development time to save costs. For example, a drug manufacturer who can trim development time by 19% can save up to USD 100 million. But if a drug is getting delayed to reach the market, the time delay costs the company around USD 1 million a day. So, pharmaceutical companies today are designing the supply chain to be as responsive as possible to reduce entry time to the market thereby increasing profit margins.
OxfordSM's pharma case studies - providing a call to actionOxfordSM
Brand teams have to be increasingly innovative when finding ways to prompt patients and physicians to intervene at the right time.
Campaigns such as GSK’s Greatest Season Ever for FLONASE®, implemented last year in the United States which made the decision to prepare for the allergy season easier for patients by linking the proactive purchase of the brand to the start of the baseball season.
Providing A Call To Action:
We find that examples from within and outside of healthcare can often prompt this innovation. They act as a way of bringing in new perspectives and allowing teams to explore new avenues and new ideas.
So, in the spirit of hoping this will prompt some new ideas in your brand team, here are our favourite case studies that speak to the need to provide a call to action.
This presentation discusses innovative solutions to improving access to orphan drugs outside of Canada and examines their potential implications for Canada. It summarizes key developments in the US and Europe, including natural history studies, new approval pathways focusing on surrogate endpoints, value demonstration programs, reference networks, early dialogues, and proposals for cross-country price negotiations. The presentation concludes that Canada is at an inflection point and could consider a new, more flexible model incorporating value demonstration across the product lifecycle, real-world evidence generation, iterative approvals, and pan-Canadian decision-making for products treating small populations.
History and Progress of Pharmacovigilance, Significance of Safety Monitoring, Pharmacovigilance in India And International Aspects, WHO International Drug Monitoring Programme, WHO and Regulatory Terminologies of ADR, Evaluation of Medication Safety, Establishing Pharmacovigilance Centres in Hospitals, Industry and National Programmes Related to Pharmacovigilance, Roles and Responsibilities in Pharmacovigilance, International Non-Proprietary Names for Drugs, International Classification of Diseases, Passive and Active Surveillance, Comparative Observational Studies, Targeted Clinical Investigations and Vaccine Safety Surveillance, Aris G Pharmacovigilance, VigiFlow, Statistical Methods for Evaluating Medication Safety Data
Patent Oppositions Database: technology that helps in the fight for affordabl...mysociety
This was presented by Sophia Apostolia from Médecins
Sans Frontières at the Impacts of Civic Technology Conference (TICTeC2016) in Barcelona on 28th April. You can find out more information about the conference here: https://www.mysociety.org/research/tictec-2016/
Merck: Global Health and Access to MedicinesTony Sebastian
Merck is a global pharmaceutical company that developed many important drugs and vaccines. It faces issues in pricing policies, patents, and expanding access to medicine in developing countries with poor infrastructure and low incomes. Merck addresses these issues through initiatives like ACHAP in Botswana and Accelerating Access Initiative that provide HIV medicines at discounted prices. It also has a differential pricing policy that sets prices based on a country's development level and disease burden. Merck works to improve access while maintaining incentives for drug innovation through partnerships and tailored pricing strategies.
The document discusses the evolving role of patient advocacy groups in orphan drug development. It notes that historical barriers to orphan drug research included limited funding, lack of researcher interest, and few patient groups. The 1983 Orphan Drug Act and similar European regulations aimed to incentivize orphan drug development by providing tax credits, reduced fees, and extended market exclusivity for sponsors. Both the FDA and EMA have increasingly engaged with patient groups over the past few decades. Industry and patient groups both seek collaboration to advance research, though their needs differ. Frameworks like the EFPIA and CTTI guidelines provide recommendations for transparent and ethical partnerships between stakeholders.
Similar to Patent Pooling and the Experience of the MPP (20)
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
1. Patent Pooling and the
Experience of the MPP–
A model
for sharing the value of innovation to ensure access
2. The MPP Background
Created to increase access to quality,
appropriate medicines for people living with
HIV in developing countries
Works by addressing a key challenge in HIV
medicines access: the need to share patents
Founded at the request of the international
community in 2010 through the innovative
financing mechanism UNITAID
Endorsed by WHO, the UN High Level Meeting on
AIDS, and the Group of 8 as a promising approach
to improving access to HIV medicines
3. The Treatment Gap
35.3
million people
live with HIV
worldwide and will
eventually need
treatment
26
million need
treatment now*
9.7
have it
*According to the WHO
Source: UNAIDS, WHO
4. MPP: Driving Innovation and
Access for Developing Countries
MILLIONS WAIT
FOR LIFE-SAVING
HIV TREATMENT.
How can we deliver?
Share Patents
• “Pool” patents &
technology through a
collaborative
voluntary licensing
system
• Create win-win
solutions for all
stakeholders
Advancing innovation,
access, and public health
Reward
Innovation
Spur New
Innovation
• Ensure continued
incentives for
innovation
• Facilitate
innovations
targeted at
developing
countries
• Enable development
of new fixed dose
combinations that
address treatment
needs
• Promote development
of adapted
formulations for
children
Ensure Access
• Accelerate
availability of more
affordable versions
of new ARVs in
developing countries
• Ensure access to
innovative products
in developing
countries
5. Needed HIV Medicines
Newer medicines
recommended by
the World Health
Organization
Fixed-dose
combinations
simplify treatment,
increase adherence
Special
formulations
needed for children
living with HIV
At this moment in time, the world faces both a great challenge
and a great opportunity in the fight against the HIV epidemic.
6. Increased Patenting of ARVs in
Developing Countries
Median number of developing countries in which basic
patents on ARV were filed (out of 75)
40
35
30
25
20
15
10
5
0
Pre-1995 ARVs
Post-1995 ARVs
Source: Medicines Patent Pool Patent Status
Database on Selected ARVs
6
7. How the MPP works
PATENT
HOLDERS
GENERIC
MANUFACTURERS
SubLicences
Licences
PEOPLE LIVING
WITH HIV
Medicines
ROYALTIES
Prioritise HIV
Medicines
Invite patent
holders to
negotiate
Negotiate
public-health
licences
Sign
agreements
Sub-licence
to generics
Manage
licensees
Increase
access
8. Promoting FDCs
through Patent Sharing
Generic access
Generic access
Patented
Generic access
Generic access
Patented, but
licensed to MPP
• Fixed-dose combinations
improve treatment adherence
for adults and children alike
U
• But face particular patent
challenges:
• Patents on just one
component can have
impact on access to
entire regimen
• There are also patents
on the combinations
themselves
9. The Public Health Perspective
• MPP seeks public health orientated
licenses covering:
– Widest number of developing countries
– Highest proportion of PLWHIV
– Non-restrictive terms to ensure competition
– Tech transfer provisions
– Flexibility to use in combinations
– Full transparency of terms
(These go beyond traditional B2B licensing
agreement between generic and originator )
11. Results to-date
• Licenses signed on 7 priority ARVs, including
WHO preferred 1st line treatment for both
adults and children
• 6 ARV manufacturers have licensed from the
MPP and are working on the development
and registration to cover up to 100 to 118
developing countries.
• 1 hybrid agreement includes price reduction
(90%) of brand product covering 138
countries
11
12. Work In Progress
• Started negotiation for a key WHO preferred
pediatric treatment.
• In advanced negotiation for the two most
important awaited new ARVs.
• Finalizing agreements with 2 HIV
manufactures to develop and manufacture
paediatric medicines.